Karyopharm Cash from 2010 to 2025
| KPTI Stock | USD 4.13 0.07 1.67% |
Cash | First Reported 2011-12-31 | Previous Quarter 62.5 M | Current Value 38.8 M | Quarterly Volatility 52.5 M |
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 604.8 K, Interest Expense of 39.3 M or Selling General Administrative of 71.8 M, as well as many indicators such as Price To Sales Ratio of 8.08, Dividend Yield of 0.0 or Days Sales Outstanding of 54.26. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
Karyopharm | Cash | Build AI portfolio with Karyopharm Stock |
Latest Karyopharm Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Karyopharm Therapeutics over the last few years. Cash refers to the most liquid asset of Karyopharm Therapeutics, which is listed under current asset account on Karyopharm Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Karyopharm Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Karyopharm Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Karyopharm Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Karyopharm Cash Regression Statistics
| Arithmetic Mean | 85,590,886 | |
| Geometric Mean | 48,201,032 | |
| Coefficient Of Variation | 67.10 | |
| Mean Deviation | 47,448,386 | |
| Median | 85,918,000 | |
| Standard Deviation | 57,428,637 | |
| Sample Variance | 3298T | |
| Range | 190.1M | |
| R-Value | 0.39 | |
| Mean Square Error | 2993.9T | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | 4,714,242 | |
| Total Sum of Squares | 49470.7T |
Karyopharm Cash History
Other Fundumenentals of Karyopharm Therapeutics
Karyopharm Therapeutics Cash component correlations
Click cells to compare fundamentals
About Karyopharm Therapeutics Financial Statements
Investors use fundamental indicators, such as Karyopharm Therapeutics' Cash, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Currently Active Assets on Macroaxis
| IGIB | iShares 5 10 Year | |
| SPTL | SPDR Barclays Long | |
| SCHH | Schwab REIT ETF | |
| SPMB | SPDR Portfolio Mortgage | |
| SPTI | SPDR Portfolio Intermediate |
Check out the analysis of Karyopharm Therapeutics Correlation against competitors. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.87) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.